These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 38252427)

  • 21. SWI/SNF gene variants and glioma risk and outcome.
    Amankwah EK; Thompson RC; Nabors LB; Olson JJ; Browning JE; Madden MH; Egan KM
    Cancer Epidemiol; 2013 Apr; 37(2):162-5. PubMed ID: 23276717
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Glioblastoma: pathology, molecular mechanisms and markers.
    Aldape K; Zadeh G; Mansouri S; Reifenberger G; von Deimling A
    Acta Neuropathol; 2015 Jun; 129(6):829-48. PubMed ID: 25943888
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Brd4-bound enhancers drive cell-intrinsic sex differences in glioblastoma.
    Kfoury N; Qi Z; Prager BC; Wilkinson MN; Broestl L; Berrett KC; Moudgil A; Sankararaman S; Chen X; Gertz J; Rich JN; Mitra RD; Rubin JB
    Proc Natl Acad Sci U S A; 2021 Apr; 118(16):. PubMed ID: 33850013
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A comprehensive prognostic signature for glioblastoma patients based on transcriptomics and single cell sequencing.
    Fan F; Zhang H; Dai Z; Zhang Y; Xia Z; Cao H; Yang K; Hu S; Guo Y; Ding F; Cheng Q; Zhang N
    Cell Oncol (Dordr); 2021 Aug; 44(4):917-935. PubMed ID: 34142341
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Integrative functional genomics identifies RINT1 as a novel GBM oncogene.
    Quayle SN; Chheda MG; Shukla SA; Wiedemeyer R; Tamayo P; Dewan RW; Zhuang L; Huang-Hobbs E; Haidar S; Xiao Y; Ligon KL; Hahn WC; Chin L
    Neuro Oncol; 2012 Nov; 14(11):1325-31. PubMed ID: 23074196
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comprehensive genetic alteration profiling in primary and recurrent glioblastoma.
    Neilsen BK; Sleightholm R; McComb R; Ramkissoon SH; Ross JS; Corona RJ; Miller VA; Cooke M; Aizenberg MR
    J Neurooncol; 2019 Mar; 142(1):111-118. PubMed ID: 30535594
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Correlation of genetic alterations by whole-exome sequencing with clinical outcomes of glioblastoma patients from the Lebanese population.
    Saadeh FS; Morsi RZ; El-Kurdi A; Nemer G; Mahfouz R; Charafeddine M; Khoury J; Najjar MW; Khoueiry P; Assi HI
    PLoS One; 2020; 15(11):e0242793. PubMed ID: 33237934
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Genomic Landscape of
    Schoenfeld AJ; Bandlamudi C; Lavery JA; Montecalvo J; Namakydoust A; Rizvi H; Egger J; Concepcion CP; Paul S; Arcila ME; Daneshbod Y; Chang J; Sauter JL; Beras A; Ladanyi M; Jacks T; Rudin CM; Taylor BS; Donoghue MTA; Heller G; Hellmann MD; Rekhtman N; Riely GJ
    Clin Cancer Res; 2020 Nov; 26(21):5701-5708. PubMed ID: 32709715
    [TBL] [Abstract][Full Text] [Related]  

  • 29. IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy.
    Li H; Li J; Cheng G; Zhang J; Li X
    Clin Neurol Neurosurg; 2016 Dec; 151():31-36. PubMed ID: 27764705
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comprehensive analysis of Reverse Phase Protein Array data reveals characteristic unique proteomic signatures for glioblastoma subtypes.
    Patil V; Mahalingam K
    Gene; 2019 Feb; 685():85-95. PubMed ID: 30401645
    [TBL] [Abstract][Full Text] [Related]  

  • 31. IDH1 mutation as a potential novel biomarker for distinguishing pseudoprogression from true progression in patients with glioblastoma treated with temozolomide and radiotherapy.
    Motegi H; Kamoshima Y; Terasaka S; Kobayashi H; Yamaguchi S; Tanino M; Murata J; Houkin K
    Brain Tumor Pathol; 2013 Apr; 30(2):67-72. PubMed ID: 22752663
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular Classification of Gliomas is Associated with Seizure Control: A Retrospective Analysis.
    Easwaran TP; Lancki N; Henriquez M; Vortmeyer AO; Barbaro NM; Scholtens DM; Ahmed AU; Dey M
    Neuromolecular Med; 2021 Jun; 23(2):315-326. PubMed ID: 33206320
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Somatic mutations associated with MRI-derived volumetric features in glioblastoma.
    Gutman DA; Dunn WD; Grossmann P; Cooper LA; Holder CA; Ligon KL; Alexander BM; Aerts HJ
    Neuroradiology; 2015 Dec; 57(12):1227-37. PubMed ID: 26337765
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genomic profiling of ovarian clear cell carcinoma in Chinese patients reveals potential prognostic biomarkers for survival.
    Ye S; Zhou S; Wu Y; Pei X; Jiang W; Shi W; Yang W; Zhou X; Shan B; Yang H
    Ann Med; 2023 Dec; 55(1):2218104. PubMed ID: 37272300
    [TBL] [Abstract][Full Text] [Related]  

  • 35. TP53 Mutation and Extraneural Metastasis of Glioblastoma: Insights From an Institutional Experience and Comprehensive Literature Review.
    Zhang X; Katsakhyan L; LiVolsi VA; Roth JJ; Rassekh CH; Bagley SJ; Nasrallah MP
    Am J Surg Pathol; 2021 Nov; 45(11):1516-1526. PubMed ID: 34366423
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SMARCB1-deficient and SMARCA4-deficient Malignant Brain Tumors With Complex Copy Number Alterations and TP53 Mutations May Represent the First Clinical Manifestation of Li-Fraumeni Syndrome.
    Hasselblatt M; Thomas C; Federico A; Nemes K; Johann PD; Bison B; Bens S; Dahlum S; Kordes U; Redlich A; Lessel L; Pajtler KW; Mawrin C; Schüller U; Nolte K; Kramm CM; Hinz F; Sahm F; Giannini C; Penkert J; Kratz CP; Pfister SM; Siebert R; Paulus W; Kool M; Frühwald MC
    Am J Surg Pathol; 2022 Sep; 46(9):1277-1283. PubMed ID: 35446794
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The preliminary radiogenomics association between MR perfusion imaging parameters and genomic biomarkers, and their predictive performance of overall survival in patients with glioblastoma.
    Liu X; Mangla R; Tian W; Qiu X; Li D; Walter KA; Ekholm S; Johnson MD
    J Neurooncol; 2017 Dec; 135(3):553-560. PubMed ID: 28889246
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A genomic score to predict local control among patients with brain metastases managed with radiation.
    Lamba N; Cagney DN; Catalano PJ; Kim D; Elhalawani H; Haas-Kogan DA; Wen PY; Wagle N; Aizer AA
    Neuro Oncol; 2023 Oct; 25(10):1815-1827. PubMed ID: 37260393
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biallelic TP53 gain of function mutations in rapidly progressing solid tumors.
    Sande CM; Chang B; Monga V; Bossler AD; Ma D
    Cancer Genet; 2018 Apr; 222-223():20-24. PubMed ID: 29666004
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular Study of Long-Term Survivors of Glioblastoma by Gene-Targeted Next-Generation Sequencing.
    Cantero D; Rodríguez de Lope Á; Moreno de la Presa R; Sepúlveda JM; Borrás JM; Castresana JS; D'Haene N; García JF; Salmon I; Mollejo M; Rey JA; Hernández-Laín A; Meléndez B
    J Neuropathol Exp Neurol; 2018 Aug; 77(8):710-716. PubMed ID: 30010995
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.